Interferons, immunity and cancer immunoediting
The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index.
Abstract
A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a cytokine which promotes increased tumour immunogenicity and often used to assess T-cell activation31”
From Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis (2016) · cites this paper as [31]
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 1×
“However, it remains unclear whether the tumour-suppressor functions of RNaseL depend on IFN”
BackgroundRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Using a combination of histological and gene-expression analyses, Galon et al”
MethodCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“These pathways coordinately defend cells from the oncogenic and/or genotoxic stimuli that can lead to malignant transformatio”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundSelf-citationMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citation
Research works printed but not linked: 1
- Yang, J., Murphy, T. L., Ouyang, W. & Murphy, K. M. Induction of interferon-γ production in TH1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29, 548–555 (1999). · DOI · Paper page
Cited by
Items 801–900 of 1,002
Topolewski, P., Zakrzewska, K. E., Walczak, J., Nienałtowski, K., Müller‐Newen, G., Singh, A., & Komorowski, M. (2022) · Science Signaling · doi:10.1126/scisignal.abd9303 · Cited by 37
Shi, Z., & Rockey, D. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.164863 · Cited by 26
Hulíková, K., Svoboda, J., Benson, V., Grobárová, V., & Fišerová, A. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.02.009 · Cited by 26
Nakashima, H., Miyake, K., Clark, C. R., Bekisz, J., Finbloom, J. A., Husain, S. R., Baron, S., Puri, R. K., & Zoon, K. C. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1152-x · Cited by 26
“Additionally, it is reported that IFNs responsiveness in the host hematopoietic compartment is necessary and sufficient to evoke antitumor activity, suggesting that the crucial targets of IFNs responses are the host cells rather than the tumor cells [28].”
Ridolfi, L., Rosa, F. D., Ridolfi, R., Gentili, G., Valmorri, L., Scarpi, E., Parisi, E., Romeo, A., & Guidoboni, M. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0262-6 · Cited by 28
“Within this context, the “immunoediting hypothesis” suggests that the host’s immune system is capable of edit for the survival of tumors that become resistant to immune cells by eliminating cancer cells sensitive to immune attack [1-5].”
BackgroundShimizu, K., Asakura, M., & Fujii, S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003351 · Cited by 26
Cell Surface CD74–MIF Interactions Drive Melanoma Survival in Response to Interferon-γ
Tanese, K., Hashimoto, Y., Berkova, Z., Wang, Y., Samaniego, F., Lee, J. E., Ekmekçioglu, S., & Grimm, E. A. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.259 · Cited by 27
Yi, B.-R., Kang, N.-H., Hwang, K., Kim, S. U., Jeung, E., & Choi, K. (2011) · PubMed · Cited by 31
Battella, S., Cox, M. C., Scaleia, R. L., Napoli, A. D., Landro, F. D., Porzia, A., Franchitti, L., Mainiero, F., Ruco, L., Monarca, B., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2026-7 · Cited by 26
The Dendritic Cell Dilemma in the Skin: Between Tolerance and Immunity
Scheib, N., Tiemann, J., Becker, C., Probst, H. C., Raker, V., & Steinbrink, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929000 · Cited by 27
“Melanoma-recruited pDC lose the propensity to produce type I interferons (IFN I), which play an important role in cancer immunization (54, 55).”
BackgroundThe Microbiome-Immune Axis Therapeutic Effects in Cancer Treatments
Son, Y. M., & Kim, J. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2208.08002 · Cited by 26
Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma
Cheng, X., Zeng, Z., Yang, H., Chen, Y., Liu, Y., Zhou, X., Zhang, C., & Wang, G. (2023) · BMC Cancer · doi:10.1186/s12885-023-10584-0 · Cited by 26
“Then, the type II IFN response not only promotes immune responses to microorganisms, but also participates in cancer immunosurveillance [45].”
BackgroundIDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation
Muller, A. J., Mondal, A., Dey, S., & Prendergast, G. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1165298 · Cited by 25
“In contrast to IFNg, which is generally considered to be anti-tumorigenic (42), IL6 is an inflammatory cytokine with pro-tumorigenic properties including the ability to support angiogenesis (43).”
BackgroundWang, B., Zhou, B., Chen, J., Sun, X. H., Yang, W., Yang, T., Yu, H., Chen, P., Chen, K., Huang, X., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007808 · Cited by 25
“1 2 The most exciting approach has been the immune checkpoint inhibitors, particularly programmed cell death protein 1/programmed cell death ligand 1 (PD-1/”
BackgroundNuclear HMGB1 is critical for CD8 T cell IFN-γ production and anti-tumor immunity
Xu, Z., Ma, W., Wang, J., Chen, H., Li, H., Yin, Z., Hao, J., & Chen, K. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114591 · Cited by 25
STAT2 hypomorphic mutant mice display impaired dendritic cell development and antiviral response
Chen, L., Wei, P., Liu, T., Kao, C.-H., Pai, L., & Lee, C. (2009) · Journal of Biomedical Science · doi:10.1186/1423-0127-16-22 · Cited by 25
“Other than regulating innate and adaptive immune response, type I and II IFNs also play important roles in cancer immunosurveillance and immunoediting, which place IFNs in a critical position in anticancer therapy [5].”
BackgroundIncreased CD112 Expression in Methylcholanthrene-Induced Tumors in CD155-Deficient Mice
Nagumo, Y., Iguchi‐Manaka, A., Yamashita-Kanemaru, Y., Abe, F., Bernhardt, G., Shibuya, A., & Shibuya, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112415 · Cited by 25
“CTL and NK cells [2,3], resulting in their secretion of cytokines and cytotoxicity against tumors [4,5].”
BackgroundCytokine-induced tumor suppressors: A GRIM story
Kalvakolanu, D. V., Nallar, S. C., & Kalakonda, S. (2010) · Cytokine · doi:10.1016/j.cyto.2010.03.009 · Cited by 25
“The IFN family of cytokines protects hosts against infectious agents and neoplastic cell growth by two mechanisms: 1) by directly activating gene expression cascades in the target cell; and 2) by promoting specific immunity against pathogen or tumor-derived antigens [29–32].”
Brunet, L. R., Hagemann, T., Gaya, A. M., Mudan, S., & Marabelle, A. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1112942 · Cited by 27
Role of interferon in melanoma: old hopes and new perspectives
Sanlorenzo, M., Vujic, I., Carnevale‐Schianca, F., Quaglino, P., Gammaitoni, L., Fierro, M. T., Aglietta, M., & Sangiolo, D. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1289169 · Cited by 28
“Their activation leads to the formation of STAT1 homodimers that enter the nucleus and bind promoters at IFNγ-activated sites (GASs) and induce gene transcription in conjunction with coactivators, such as CBP (cyclic-AMP-responsive-element-binding protein (CREB)-binding protein), p300, and minichromosome maintenance d…”
BackgroundInfluentialLiu, Q., Hua, M., Zhang, C., Wang, R., Liu, J., Yang, X., Han, F., Hou, M., & Ma, D. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.014 · Cited by 26
Too much of a good thing: Detrimental effects of interferon
Reich, N. C. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101282 · Cited by 24
Dysregulation of janus kinases and signal transducers and activators of transcription in cancer.
Costa‐Pereira, A. P., Bonito, N. A., & Seckl, M. J. (2011) · Europe PMC (PubMed Central) · Cited by 27
Adoptive Immunotherapy with Cl-IB-MECA-Treated CD8+ T Cells Reduces Melanoma Growth in Mice
Montinaro, A., Forte, G., Sorrentino, R., Luciano, A., Palma, G., Arra, C., Adcock, I. M., Pinto, A., & Morello, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045401 · Cited by 24
“This effect was accompanied by increased levels of Th1-like and cytotoxic cytokines in the tumor milieu, which are critical for antitumor activity in the host [22,23].”
BackgroundExploiting tumor epigenetics to improve oncolytic virotherapy
Forbes, N. E., Abdelbary, H., Lupien, M., Bell, J. C., & Diallo, J. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00184 · Cited by 25
“As previously discussed, the majority (but not all) of cancer cells are dysfunctional in their ability to produce and/or respond to IFN (Dunn et al., 2006).”
BackgroundInfluentialModulation of IFN-γ Receptor 1 Expression by AP-2α Influences IFN-γ Sensitivity of Cancer Cells
Chen, C., Guo, L., Shi, M., Hu, M., Hu, M., Yu, M., Wang, T., Song, L., Shen, B., Lu, Q., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.10.040 · Cited by 24
Novel roles of the CCR4–NOT complex
Chapat, C., & Corbo, L. (2014) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1254 · Cited by 26
Zhang, L., Wang, S., Liu, Z., Zhang, L., Wang, S., & Wang, B. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.04.007 · Cited by 25
On taking the STING out of immune activation
Banete, A., Seaver, K., Bakshi, D., Gee, K., & Basta, S. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mir0917-383r · Cited by 25
Liu, C., Li, Z., Wang, S., Fan, Y., Zhang, S., Yang, X., Hou, K., Tong, J., Hu, X., Shi, X., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2761-y · Cited by 24
TGF-β signalling and immunity in prostate tumourigenesis
Diener, K. R., Need, E. F., Buchanan, G., & Hayball, J. D. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903544507 · Cited by 26
“In this model, an initial lag in prostate tumourigenesis was observed [116], with results also suggesting that other genetic changes are necessary to inhibit T cell-mediated surveillance of malignant change [96].”
BackgroundShedding Light on Melanocyte Pathobiology In Vivo
Zaidi, M. R., Fabo, E. C. D., Noonan, F. P., & Merlino, G. T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2586 · Cited by 24
Interferon gamma/NADPH oxidase defense system in immunity and cancer
Hodný, Z., Reiniš, M., Hubáčková, S., Vašicová, P., & Bártek, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1080416 · Cited by 25
“Besides its function in antiviral and antibacterial immunity, the crucial role of IFNg in tumor immunosurveillance/anticancer immunity, as well as in cancer immunoediting, is well documented.(1) In simple terms, the anticancer effects of IFNg are bimodal.”
BackgroundThe role of interferon-gamma and its receptors in gastrointestinal cancers
Mozooni, Z., Golestani, N., Bahadorizadeh, L., Yarmohammadi, R., Jabalameli, M., & Amiri, B. S. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154636 · Cited by 24
Targeting Cytotoxic T-Lymphocyte Antigen 4 in Immunotherapies for Melanoma and Other Cancers
Page, D. B., Yuan, J. D., & Wolchok, J. D. (2010) · Immunotherapy · doi:10.2217/imt.10.21 · Cited by 24
Immunobiology of hepatocellular carcinoma
Flecken, T., Spangenberg, H. C., & Thimme, R. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0783-x · Cited by 23
Liu, X., Dowell, A. C., Patel, P., Viney, R., Foster, M. C., Porfiri, E., James, N. D., & Bryan, R. T. (2014) · Future Oncology · doi:10.2217/fon.14.79 · Cited by 25
“It is this element of the 82 immune response which is believed to be key to anti-tumour responses (14).”
BackgroundSTAT-1 expression in human glioblastoma and peritumoral tissue.
Haybaeck, J., Obrist, P., Schindler, C., Spizzo, G., & Doppler, W. (2007) · PubMed · Cited by 27
Ramos, R. N., de Oliveira, C. E., Gasparoto, T. H., Malaspina, T. S. D. S., Belai, E. B., Cavassani, K. A., Garlet, G. P., Silva, J. S., & Campanelli, A. P. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs103 · Cited by 24
Role of Immunotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer
Rijavec, E., Genova, C., Alama, A., Barletta, G., Sini, C., Pronzato, P., Coco, S., Bello, M. G. D., Savarino, G., Truini, A., et al. (2013) · Future Oncology · doi:10.2217/fon.13.145 · Cited by 26
A New Rat Model of Cisplatin-induced Neuropathic Pain
Lin, H., Heo, B. H., & Yoon, M. H. (2015) · The Korean journal of pain · doi:10.3344/kjp.2015.28.4.236 · Cited by 23
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials.
Paniccia, A., Merkow, J. S., Edil, B. H., & Zhu, Y. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2015.05.01 · Cited by 28
“Immunoediting is composed primarily of three sequential stages known as elimination, equilibrium, and escape (7,14,16).”
BackgroundLyu, X., Zhu, X., Zhao, M., Zuo, X., Huang, Z., Liu, X., Jiang, T., Yang, X., Li, X., Long, X., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1537 · Cited by 23
Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade
Heath, B. R., Michmerhuizen, N. L., Donnelly, C. R., Sansanaphongpricha, K., Sun, D., Brenner, J. C., & Lei, Y. L. (2019) · Journal of Dental Research · doi:10.1177/0022034519864112 · Cited by 23
Intrahepatic immune changes after hepatitis c virus eradication by direct‐acting antiviral therapy
Amaddeo, G., Nguyễn, C. T., Maillé, P., Mulé, S., Luciani, A., Machou, C., Rodrigues, A., Regnault, H., Mallat, A., Laurent, A., et al. (2019) · Liver International · doi:10.1111/liv.14226 · Cited by 26
Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure
Viganó, S., Bobisse, S., Coukos, G., Perreau, M., & Harari, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01350 · Cited by 24
“The immunogenicity of the tumor is shaped by the immune system through a process called “immunoediting,” as the pivotal work of Bob Schreiber first showed 15 years ago (116).”
BackgroundAugé, H., Notarantonio, A., Morizot, R., Quinquenel, A., Fornecker, L., Hergalant, S., Feugier, P., & Broséus, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594841 · Cited by 23
“Oncogenic processes begin with an acute inflammatory response, with tumor infiltration by non-specific innate immune cells and increased production of pro-inflammatory cytokines, followed by an activating cascade specific of adaptive immune cells (71, 72).”
BackgroundTherapeutic Down-Modulators of Staphylococcal Superantigen-Induced Inflammation and Toxic Shock
Krakauer, T. (2010) · Toxins · doi:10.3390/toxins2081963 · Cited by 26
Oesophageal squamous cell carcinoma in a young adult with IL-12Rβ1 deficiency
Cárdenes, M., Ángel-Moreno, A., Fieschi, C., Sologuren, I., Colino, E., Molinés, A., García-Laorden, M. I., Campos-Herrero, M. I., Andújar, M., Casanova, J., et al. (2010) · Journal of Medical Genetics · doi:10.1136/jmg.2009.071910 · Cited by 23
“In fact, the development of IFN-g insensitivity is one of the mechanisms that allow tumours to escape from elimination by the immune response.(2) IL-12 was also shown to cause a remarkable reduction in ultravioletinduced DNA lesions, and IL-12 deficient mice are more sensible to ultraviolet-induced skin tumours than t…”
BackgroundInfluentialMonti, M., Ferrari, G., Grosso, V., Missale, F., Bugatti, M., Cancila, V., Zini, S., Segala, A., Via, L. L., Consoli, F., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1227648 · Cited by 24
“…DNA through cGAS – STING (stimulator of interferon genes) pathway eliciting a potent I-IFN production independently of TLR7/9 (13 – 15). interferon-a (IFN-a ) production directly affects tumor growth by inducing cell-cycle arrest and apoptosis of cancer cells and inhibiting angiogenesis (16, 17).”
BackgroundNarkwa, P. W., Blackbourn, D. J., & Mutocheluh, M. (2017) · Infectious Agents and Cancer · doi:10.1186/s13027-017-0127-8 · Cited by 30
“One component of the JAK-STAT-ISRE signalling pathway considered to have tumour suppressor function is STAT1 [28].”
BackgroundHarper, J. A., Burke, S., Travers, J., Rath, N., Leinster, A., Navarro, C., Franks, R., Leyland, R., Mulgrew, K. A., McGlinchey, K., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0902 · Cited by 23
Angiogenesis meets immunology: Cytokine gene therapy of cancer
Minuzzo, S. A., Moserle, L., Indraccolo, S., & Amadori, A. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.12.008 · Cited by 26
Kaur, S., Kroczynska, B., Sharma, B., Sassano, A., Arslan, A. D., Majchrzak-Kita, B., Stein, B. L., McMahon, B., Altman, J. K., Su, B., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537852 · Cited by 21
Menéndez, J. A. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1155 · Cited by 24
Du, W., Leigh, N. D., Bian, G., O’Neill, R., Mei, L., Qiu, J., Chen, G. L., Hahn, T., Liu, H., McCarthy, P. L., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500668 · Cited by 22
Zare, F., Dehghan-Manshadi, M., & Mirshafiey, A. (2016) · Reumatismo · doi:10.4081/reumatismo.2015.851 · Cited by 22
The Synthetic Parasite-Derived Peptide GK1 Increases Survival in a Preclinical Mouse Melanoma Model
Pérez‐Torres, A., Vera-Aguilera, J., Hernaiz‐Leonardo, J. C., Moreno-Aguilera, E., Monteverde-Suárez, D., Vera-Aguilera, C., & Estrada-Bárcenas, D. A. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1438 · Cited by 22
“In addition, IFN-c is known to mediate antitumor activity through its antiangiogenic effects.(34) Together, these effects might explain the presence of numerous apoptotic tumoral cells and the significantly greater necrotic areas in the GK1treated mice than in the control mice.”
BackgroundYassin, M., Sadowska, Z., Tritsaris, K., Kissow, H., Hansen, C. H. F., Forman, J. L., Rogler, G., Troelsen, J. T., Pedersen, A. E., & Olsen, J. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy112 · Cited by 23
Driessens, G., Gordower, L., Nuttin, L., Stordeur, P., Blocklet, D., Egrise, D., Velu, T. J., & Bruyns, C. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0500-y · Cited by 22
“It has been previously shown that IFN- is crucial for tumor rejection especially by increasing tumor immunogenicity via the up-regulation of the MHC class I pathway of antigen processing and presentation (reviewed in [7]).”
BackgroundBanerjee, A., Narasimhulu, C. A., & Singla, D. K. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00378.2023 · Cited by 23
Jung, J. M., Kim, Y., Chang, S. E., Lee, M. W., Won, C. H., & Lee, W. J. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05387-6 · Cited by 22
“The key role of IL-12 and IL-23 in developing of antitumor and protumor immunity, respectively, has been described (Dunn et al. 2006; Langowski et al. 2006).”
BackgroundThe role of CD8 PET imaging in guiding cancer immunotherapy
Zhang, J., Du, B., Wang, Y., Cui, Y., Wang, S., Zhao, Y., Li, Y., & Li, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1428541 · Cited by 24
“Studies have also investigated the feasibility of using IFN-g as a therapeutic agent in immunotherapy (110, 111).”
BackgroundRegulation of snoRNAs in Cancer: Close Encounters with Interferon
Nallar, S. C., & Kalvakolanu, D. V. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0106 · Cited by 24
Immunotherapy based approaches in myelofibrosis
Masárová, L., Verstovšek, S., Kantarjian, H. M., & Daver, N. G. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1366853 · Cited by 21
Tumor inherent interferons: Impact on immune reactivity and immunotherapy
Brockwell, N. K., & Parker, B. S. (2018) · Cytokine · doi:10.1016/j.cyto.2018.04.006 · Cited by 21
Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer
Cai, J., Liu, W., Wong, C.-W., Zhu, W., Lin, Y., Hu, J. X., Xu, W., Zhang, J., Sander, M., Wang, Z., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01416-7 · Cited by 23
“On the other hand, they also activate the anti-tumor immunity through cytotoxic T cells and NK cells stimulation, tumor-suppressive immune cells inhibition and cancer immunoediting [10, 12].”
BackgroundMehdizadeh, R., Shariatpanahi, S. P., Goliaei, B., Peyvandi, S., & Rüegg, C. (2021) · Cancers · doi:10.3390/cancers13020245 · Cited by 23
State-of-the-Art Management of Renal Cell Carcinoma
Mourad, W. F., Dutcher, J. P., & Ennis, R. D. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31825d5522 · Cited by 23
“It also has antiproliferative effects on hematopoietic cells and potentially direct effects on tumor cells.(57) Long-term survivors after treatment with interferon are reported.”
BackgroundLiu, X., Lu, J., He, M., Li, Z., Zhang, B., Zhou, L., Li, Q., Li, G., Wang, L., Tian, W.-D., et al. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912800673293 · Cited by 21
Histone Deacetylases Inhibit IFN-γ-Inducible Gene Expression in Mouse Trophoblast Cells
Choi, J. C., Holtz, R., & Murphy, S. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802454 · Cited by 24
Cancer Prevention: Lessons Learned and Future Directions
Dunn, B. K., & Kramer, B. S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.11.003 · Cited by 21
Vito, A. D., Orecchia, P., Balza, E., Reverberi, D., Scaldaferri, D., Taramelli, R., Noonan, D. M., Acquati, F., & Mortara, L. (2020) · Cancers · doi:10.3390/cancers12030717 · Cited by 23
The added value of type I interferons to cytotoxic treatments of cancer
Bracci, L., Sistigu, A., Proietti, E., & Moschella, F. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.008 · Cited by 21
Nie, W., Yu, T., Liu, X., Wang, B., Li, T., Wu, Y., Zhou, X., Ma, L., Lin, Y., Qian, Z., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.03.031 · Cited by 20
DLEU1 promotes oral squamous cell carcinoma progression by activating interferon-stimulated genes
Hatanaka, Y., Niinuma, T., Kitajima, H., Nishiyama, K., Maruyama, R., Ishiguro, K., Toyota, M., Yamamoto, E., Kai, M., Yorozu, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99736-5 · Cited by 20
PI3K/Akt/mTOR, a Pathway Less Recognized for Staphylococcal Superantigen-Induced Toxicity
Krakauer, T. (2012) · Toxins · doi:10.3390/toxins4111343 · Cited by 24
Dissanayake, D., Murakami, K., Tran, M. D., Elford, A. R., Millar, D. G., & Ohashi, P. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092380 · Cited by 20
“Furthermore, failures in tumor vaccination approaches have been attributed to the inherent heterogeneity and instability of tumors as a target tissue, as well as the various modes of immune evasion exhibited by tumors such as immune editing, induction and recruitment of regulatory T-cells (Tregs), expression of inhibi…”
BackgroundScarpa, M., Scarpa, M., Castagliuolo, I., Erroi, F., Basato, S., Brun, P., Angriman, I., & Castoro, C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2405-z · Cited by 20
“Background Immune surveillance of nascent cancer cells is a fundamental process mediated by T-cells, macrophages, and natural killer cells that work to protect host against the unrestrained proliferation of transformed cells [1].”
A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma
Kanzaki, H., Shinohara, F., Suzuki, M., Wada, S., Miyamoto, Y., Yamaguchi, Y., Katsumata, Y., Makihira, S., Kawai, T., Taubman, M. A., et al. (2016) · Scientific Reports · doi:10.1038/srep32259 · Cited by 20
“(1) Inhibition of the antibody binding to rADAM17: ELISA plates were coated with rADAM17 and blocked.”
BackgroundRožman, P. J. (2018) · GeroScience · doi:10.1007/s11357-018-0027-x · Cited by 20
Wilson, D. R., Jin, C., Ibrahim, J. G., & Sun, W. (2019) · Journal of the American Statistical Association · doi:10.1080/01621459.2019.1654874 · Cited by 20
Possible mechanisms of cancer prevention by nicotinamide
Buqué, A., Bloy, N., Kroemer, G., & Galluzzi, L. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15096 · Cited by 20
Ma, J., He, P., Zhao, C., Ren, Q., Dong, Z., Qiu, J., Yang, J. C., Liu, S., & Du, Y. (2020) · Advanced Science · doi:10.1002/advs.202000609 · Cited by 23
IL-17A is a central regulator of lung tumor growth
Reppert, S., Koch, S., & Finotto, S. (2012) · OncoImmunology · doi:10.4161/onci.19735 · Cited by 23
“It is also known to improve antigen presentation to CD8 T cells by upregulating MHCI expression.(6) Thus anti-IL-17A antibody immunotherapy might be also relevant for patients suffering from lung cancer because it can block selectively angiogenesis and tumor growth locally.”
Lü, Y., Gu, X., Chen, L., Yao, Z., Song, J., Niu, X., Xiang, R., Cheng, T., Qin, Z., Deng, W., et al. (2013) · Angiogenesis · doi:10.1007/s10456-013-9397-y · Cited by 21
Song, S., Liu, C., Wang, J., Zhang, Y., You, H., Wang, Y., Liu, F., & Sun, S. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.11.095 · Cited by 20
Inhibitory Effect of Interferon-γ on Experimental Tooth Movement in Mice
Kohara, H., Kitaura, H., Yoshimatsu, M., Fujimura, Y., Morita, Y., Eguchi, T., & Yoshida, N. (2012) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0124 · Cited by 25
Chaudhuri, A., Wilson, N. S., Yang, B., Paler-Martínez, A., Liu, J., Zhu, C. Y., Bricker, N., Couto, S. S., Modrusan, Z. D., French, D. M., et al. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.27 · Cited by 21
IFITM6 expression is increased in macrophages of tumor-bearing mice
Yang, Y. D. (2010) · Oncology Reports · doi:10.3892/or.2010.1092 · Cited by 20
“In turn, IFNs induce the expression of several genes to execute their function (4).”
BackgroundRole of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection
Ligocki, A. J., Brown, J. R., & Niederkorn, J. Y. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0315-093rrr · Cited by 23
Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After Transplantation
Dantal, J., & Campone, M. (2016) · Transplantation · doi:10.1097/tp.0000000000001428 · Cited by 20
“of immune surveillance against tumors was introduced in the late 1950s by Burnet(17) and was reinforced by the demonstration of a higher incidence of chemically induced and spontaneous tumors in immunodeficient compared with wild-type mice.(18,19) These experiments provided the working hypothesis that nascent cancers…”
BackgroundRobbins, C. T., Bou-Dargham, M. J., Sanchez, K. G., Rosen, M. C., & Sang, Q. A. (2018) · Journal of Cancer · doi:10.7150/jca.27993 · Cited by 21
“However, our results showed that IFN-I signaling is significantly inhibited by somatic driver gene mutations, indicating a potential immune evasion [80,81].”
Tan, X., Cao, F., Tang, F., Lu, C., Qiao-yan, Y., Feng, S., Yang, Z., Chen, S., He, X., He, J., et al. (2021) · Journal of Immunology Research · doi:10.1155/2021/9995869 · Cited by 19
“Activated NK cells also rapidly secrete a variety of cytokines and chemokines, such as interferon γ (IFNγ), that promote the recruitment and activation of other participants in the antitumor response [35].”
BackgroundType I and II interferon signaling in colorectal cancer liver metastasis
Mödl, B., Moritsch, S., Zwolanek, D., & Eferl, R. (2022) · Cytokine · doi:10.1016/j.cyto.2022.156075 · Cited by 20
GRIM-1, a Novel Growth Suppressor, Inhibits rRNA Maturation by Suppressing Small Nucleolar RNAs
Nallar, S. C., Lin, L., Srivastava, V., Gade, P., Hofmann, E. R., Ahmed, H., Reddy, S. P., & Kalvakolanu, D. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024082 · Cited by 19
“the neoplastic cells [1] and 2) shaping the immune response against neoplastic cells [2].”
BackgroundPark, J., Lee, J., Kang, W., Chang, S.-Y., Shin, E.-C., & Choi, C. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.42 · Cited by 19
“These dual effects of the immune system on developing tumors facilitated refinement of the cancer immunosurveillance hypothesis into the ‘cancer immunoediting’ hypothesis proposed by Schreiber et al.(5) In this project, we report novel findings relating to tumor-specific evasion of immune-mediated cell death by transf…”
BackgroundInfluentialMetović, J., Vignale, C., Annaratone, L., Osella‐Abate, S., Maletta, F., Rapa, I., Cabutti, F., Patriarca, S., Gallo, M., Nikiforov, Y. E., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa655 · Cited by 19
Nakajima, S., Mimura, K., Matsumoto, T., Min, A. K. T., Ito, M., Nakano, H., Neupane, P., Kanke, Y., Okayama, H., Saito, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-96521-2 · Cited by 22
Bennett, L. E., Abeywardena, M. Y., Burnard, S. L., Forsyth, S., Head, R. J., King, K., Patten, G. S., Watkins, P., Williams, R. P. W., Zabaras, D., et al. (2013) · Nutrition and Cancer · doi:10.1080/01635581.2013.796999 · Cited by 24
“In a biological environment of unregulated (cancer) cell proliferation that is not caused by infection (44), a T helper Type 1 protective immune response is initiated which activates ‘natural killer’ cells and IFN-γ (45).”
BackgroundInfluential
Metadata
- Authors
- Dunn, G. P., Koebel, C. M., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Schreiber, Robert D.
- Venue
- Nature Reviews Immunology
- Published
- 2006-11
- Volume
- 6
- Issue
- 11
- Pages
- 836-848
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2052313621
- Cited by
- 1,617
- References
- 119
- Citations by year
- 2026: 33 · 2025: 51 · 2024: 87 · 2023: 104 · 2022: 84 · 2021: 94 · 2020: 93 · 2019: 73 · 2018: 85 · 2017: 74 · 2016: 93 · 2015: 100 · 2014: 100 · 2013: 79 · 2012: 76
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- interferon, type I interferon, interferon-gamma, cancer immunoediting, tumor surveillance, antitumor immunity, tumor-immune interactions, interferon-alpha, interferon-beta, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunity, Immunotherapy, Interferons, Neoplasms, Monitoring, Immunologic, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.